1. Home
  2. BBIO vs CADE Comparison

BBIO vs CADE Comparison

Compare BBIO & CADE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • CADE
  • Stock Information
  • Founded
  • BBIO 2015
  • CADE 1876
  • Country
  • BBIO United States
  • CADE United States
  • Employees
  • BBIO N/A
  • CADE N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • CADE Major Banks
  • Sector
  • BBIO Health Care
  • CADE Finance
  • Exchange
  • BBIO Nasdaq
  • CADE Nasdaq
  • Market Cap
  • BBIO 6.7B
  • CADE 5.9B
  • IPO Year
  • BBIO 2019
  • CADE N/A
  • Fundamental
  • Price
  • BBIO $34.25
  • CADE $30.28
  • Analyst Decision
  • BBIO Strong Buy
  • CADE Buy
  • Analyst Count
  • BBIO 12
  • CADE 12
  • Target Price
  • BBIO $57.09
  • CADE $37.08
  • AVG Volume (30 Days)
  • BBIO 2.9M
  • CADE 1.1M
  • Earning Date
  • BBIO 04-29-2025
  • CADE 07-21-2025
  • Dividend Yield
  • BBIO N/A
  • CADE 3.63%
  • EPS Growth
  • BBIO N/A
  • CADE N/A
  • EPS
  • BBIO N/A
  • CADE 2.85
  • Revenue
  • BBIO $127,415,000.00
  • CADE $1,734,570,000.00
  • Revenue This Year
  • BBIO $89.10
  • CADE $13.43
  • Revenue Next Year
  • BBIO $57.07
  • CADE $10.60
  • P/E Ratio
  • BBIO N/A
  • CADE $10.63
  • Revenue Growth
  • BBIO N/A
  • CADE 45.52
  • 52 Week Low
  • BBIO $21.62
  • CADE $25.22
  • 52 Week High
  • BBIO $39.54
  • CADE $40.20
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 50.58
  • CADE 48.30
  • Support Level
  • BBIO $31.77
  • CADE $29.77
  • Resistance Level
  • BBIO $33.93
  • CADE $30.93
  • Average True Range (ATR)
  • BBIO 1.28
  • CADE 0.58
  • MACD
  • BBIO -0.09
  • CADE -0.18
  • Stochastic Oscillator
  • BBIO 57.14
  • CADE 17.53

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About CADE Cadence Bank

Cadence Bank is a bank based in the United States. The operating segments are Corporate Banking segment focuses on C&I, business banking, and commercial real estate lending to clients in the geographic footprint, Community Banking segment provides a broad range of banking services through the branch network to serve the needs of community businesses and individual consumers in the geographic footprint, Mortgage segment includes mortgage banking activities of originating mortgage loans, selling mortgage loans in the secondary market and servicing the mortgage loans, Banking Services segment offers individuals, businesses, governmental institutions, and non-profit entities a widerange of solutions to help protect, grow, and transfer wealth, General Corporate and Other segment.

Share on Social Networks: